FDA approves Vertex's non-opioid painkiller, first new kind of pain medicine in decades
The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive ...
Vertex Pharmaceuticals Unusual Options Activity
Financial giants have made a conspicuous bearish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex ...
Forbes7d
What's Happening With VRTX Stock?
Vertex Pharmaceuticals stock (NASDAQ: VRTX) is trending higher after the U.S. FDA approved Journavx – an oral non-opioid pain medication. This is a big win for Vertex, given that Journavx can ...
Vertex Pharmaceuticals (VRTX) Set for Painless Gains After FDA Approval
Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...
Seeking Alpha7d
VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...
Vertex Pharmaceuticals price target raised to $540 from $522 at BofA
BofA analyst Tazeen Ahmad raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $540 from $522 and keeps a Buy rating on the ...
Morningstar7d
Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.
Shares of Vertex Pharmaceuticals Inc. surged ahead of ... markets for Vertex's new treatment could be those with a prior history of addiction and obese patients where respiratory depression ...
Nasdaq8d
March 14th Options Now Available For Vertex Pharmaceuticals (VRTX)
Below is a chart showing the trailing twelve month trading history for Vertex Pharmaceuticals, Inc., and highlighting in green where the $395.00 strike is located relative to that history ...
Yahoo Finance8d
Vertex Pharmaceuticals (NASDAQ:VRTX) lifts 3.2% this week, taking five-year gains to 83%
Vertex Pharmaceuticals achieved compound earnings per share (EPS) growth of 1.5% per year. We do note that extraordinary items have impacted its earnings history. This EPS growth is lower than the ...
AFP7d
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...
NBC Washington9d
FDA approves Vertex's non-opioid painkiller, first new kind of pain medicine in decades
The Food and Drug Administration approved Vertex Pharmaceuticals' non-opioid painkiller ... It's a milestone after a long history of unsuccessful efforts to develop painkillers without the ...